Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.56 |
| ▸ | MEN1 | O00255 | 3/20 | 0.56 |
| ▸ | HPGD | P15428 | 2/20 | 0.56 |
| ▸ | GAA | P10253 | 3/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8248742 | 0.85 | SMN1; SMN2 (0.64) | ALDH1A1LMNAL3MBTL1KMT2AMEN1 | |
| SCHEMBL8241785 | 0.85 | RAB9A (0.66) | ALDH1A1LMNAL3MBTL1KMT2AHPGD | |
| SCHEMBL21026114 | 0.85 | ALDH1A1 (0.49) | ALDH1A1LMNAL3MBTL1KMT2AMEN1 | |
| SCHEMBL10765557 | 0.84 | SMN1; SMN2 (0.63) | ALDH1A1LMNAL3MBTL1KMT2AMEN1 | |
| SCHEMBL27493747 | 0.84 | ALDH1A1 (0.56) | ALDH1A1KMT2AMEN1HPGDGAA | |
| SCHEMBL20024729 | 0.83 | MAPT (0.57) | ALDH1A1LMNAL3MBTL1HPGDGAA | |
| SCHEMBL6538992 | 0.83 | GAA (0.61) | ALDH1A1LMNAL3MBTL1KMT2AHPGD | |
| SCHEMBL6539272 | 0.83 | LMNA (0.54) | ALDH1A1LMNAL3MBTL1KMT2AHPGD | |
| SCHEMBL8248620 | 0.82 | SMN1; SMN2 (0.61) | ALDH1A1LMNAL3MBTL1KMT2AMEN1 | |
| SCHEMBL21197867 | 0.82 | GAA (0.68) | ALDH1A1LMNAL3MBTL1HPGDGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230212152-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. | 2023-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230212152-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | CTRL, CTSL, CTSV | ALDH1A1 1863/4885LMNA 2202/4885L3MBTL1 544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.